Rituximab in generalized myasthenia gravis: Clinical, quality of life and cost-utility analysis

Rituximab is a clinical effective treatment for B cell-related diseases like MG and seems to be a cost-saving intervention. Its use is associated with a decrease in the need for other immunosuppressive treatments whilst improving quality of life and reducing health costs.